<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201101049215N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-22</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Gammalinolenic acid in hand eczema</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of therapeutic effect of topical GAMMANOL cream- contains 6% gamma linolenic acid- with mometasone 0/1% cream in hand eczema by two scoring systems of DLQI and HECSI  in patients with chronic or subacute hand eczema</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52017</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: In this study we compare the therapeutic effect of gammalinolenic acid with mometasone which is the main and common therapy for hand eczema, Randomization description: Randomization is based on the permutation block method with four blocks in each group, randomization list was prepared for this purpose, Blinding description: The drugs in this trial are Mometasone 0.1%  cream and Gammanol cream containing 6% gammalinolenic acid; both drugs are packed in bottles with the same shape and each one weighs 30 gr. Statistic advisor prepares a randomization list and each bottle is given a number. The participant, the main investigator, and the physician who is responsible for follow up and evaluating the outcome of drug use, have no information about the kind of drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Hand eczema.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 26 patients with chronic and subacute hand eczema who receive Gammanol cream containing 6% gammalinolenic acid, manufactured by Asacpharma company, at the rate of 30 grams. Patients must use this cream for one month, the dosage is explained to the patients during a ten minute session by Finger Tip Unit. Finger Tip Unit of a cream is equivalent to 0.5 gram for each hand and finally 30 gram is used during one month for both hands. Intervention 2: Control group:  26 patients with chronic and subacute hand eczema who receive the standard and usual therapy which is mometasone 0.1% cream, at the rate of 30 grams. Patients must use this cream for one month, the dosage is explained to the patients during a ten minute session by Finger Tip Unit. Finger Tip Unit of a cream is equivalent to 0.5 gram for each hand and finally 30 gram is used during one month for both hands.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Participants personal data, All the data is potentially available after making the people unrecognizable

When:
Start access 6 months after print result

To whom:
researchers employed in academic and scientific institutions

Conditions:
Research use of the data of this study is allowed
communication in the manner of e-mail

Where to obtain:
web page of Shiraz University of Medical Sciences, Research unit
Shahid Faghihi hospital, dermatology clinic, department office
E-mail
nedazakeri@yahoo.com

How to obtain:
After reviewing their written request, the data is given to them as soon as possible

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farideh Jokar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology clinic, Shahid Faghihi hospital, Karimkhan Zand Ave., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134846114</zip>
        <telephone>+98 71 3212 5239</telephone>
        <email>nedazakeri@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farideh Jokar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology clinic, Shahid Faghihi hospital, Karimkhan Zand Ave., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134846114</zip>
        <telephone>+98 71 3212 5239</telephone>
        <email>nedazakeri@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Chronic or subacute hand eczema, unilateral or bilateral</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Acute hand eczema
pregnant or lactating women
Use systemic immunosuppressant drug for one recent month
Use topical therapies for hand eczema for two recent weeks
To have localized infection in hands</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>XII</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disease of the skin and subcutaneous tissue</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 26 patients with chronic and subacute hand eczema who receive Gammanol cream containing 6% gammalinolenic acid, manufactured by Asacpharma company, at the rate of 30 grams. Patients must use this cream for one month, the dosage is explained to the patients during a ten minute session by Finger Tip Unit. Finger Tip Unit of a cream is equivalent to 0.5 gram for each hand and finally 30 gram is used during one month for both hands.</i_keyword>
      <i_keyword>Control group:  26 patients with chronic and subacute hand eczema who receive the standard and usual therapy which is mometasone 0.1% cream, at the rate of 30 grams. Patients must use this cream for one month, the dosage is explained to the patients during a ten minute session by Finger Tip Unit. Finger Tip Unit of a cream is equivalent to 0.5 gram for each hand and finally 30 gram is used during one month for both hands.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Han Eczema Severity Score and Dermatology Life Quality Score. Timepoint: First visit and after one month of drug use. Method of measurement: measurement table of hand eczema severity index and questionnaire of dermatologiy life quality index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Research Deputy of Shiraz University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
      <source_name>Research Deputy of Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-09</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Ethics committee of Shiraz University of Medical Sciences, University of Medical Sciences Building, Karimkhan Zand Ave., Shiraz Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
